Cargando…

Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study

INTRODUCTION: There is limited published literature on longitudinal utilization of glucose-lowering agents (GLAs) among patients with type 2 diabetes (T2D) and cardiovascular disease (CVD or risk of CVD). This retrospective, observational study aimed to provide updated evidence on patient characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Radhika, Mody, Reema, Yu, Maria, Cowburn, Stuart, Konig, Manige, Prewitt, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663782/ https://www.ncbi.nlm.nih.gov/pubmed/36131064 http://dx.doi.org/10.1007/s13300-022-01320-1

Ejemplares similares

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
por: Boye, Kristina S., et al.
Publicado: (2020)

Diabetes Mellitus and Cardiovascular Disease
por: Aganovic, Izet
Publicado: (2003)

Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting
por: Weng, Wayne, et al.
Publicado: (2020)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
por: Funck, Kristian L., et al.
Publicado: (2020)

Glucose Serum Concentrations and Cardiovascular Disease in Patients on the End Stage of Renal Disease without Diabetes Mellitus
por: Raikou, Vaia D., et al.
Publicado: (2015)

Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study
por: Chen, Guanmin, et al.
Publicado: (2021)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2021)

Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
por: Baek, Jong Ha, et al.
Publicado: (2022)

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
por: Raparelli, Valeria, et al.
Publicado: (2020)

MicroRNAs and Cardiovascular Disease in Diabetes Mellitus
por: Ding, Yue, et al.
Publicado: (2017)

Resistance Exercise and Cardiovascular Disease in Diabetes Mellitus
por: Yoon, Jin-Hwan
Publicado: (2022)

Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk
por: Colom, Cristina, et al.
Publicado: (2021)

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
por: Yang, Chun-Ting, et al.
Publicado: (2020)

Cardiovascular care guideline implementation in community health centers in Oregon: a mixed-methods analysis of real-world barriers and challenges
por: Gold, Rachel, et al.
Publicado: (2017)

Lower levels of vWF are associated with lower risk of cardiovascular disease
por: van Paridon, Pauline C. S., et al.
Publicado: (2022)

The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings
por: Athyros, Vasilios G., et al.
Publicado: (2012)

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
por: Dodick, David W., et al.
Publicado: (2020)

Real-world utilization of guideline-directed genetic testing in inherited cardiovascular diseases
por: Longoni, Mauro, et al.
Publicado: (2023)

Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus
por: Enkhmaa, Byambaa, et al.
Publicado: (2010)

Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus
por: Katakami, Naoto
Publicado: (2018)

Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease
por: Vesa, Cosmin Mihai, et al.
Publicado: (2023)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
por: Mannucci, Edoardo, et al.
Publicado: (2013)

Cardiovascular disease risk factors in a Nigerian population with impaired fasting blood glucose level and diabetes mellitus
por: Oguoma, Victor M., et al.
Publicado: (2017)

Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
por: Reaven, Peter D., et al.
Publicado: (2009)

How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients With and Without Previous Cardiovascular Disease?
por: Canoy, Dexter, et al.
Publicado: (2022)

Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
por: Bhattarai, Mukul, et al.
Publicado: (2022)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

History of Gestational Diabetes Mellitus in Relation to Cardiovascular Disease and Cardiovascular Risk Factors in US Women
por: Shostrom, Derrick C. V., et al.
Publicado: (2017)

Astaxanthin: A Potential Therapeutic Agent in Cardiovascular Disease
por: Fassett, Robert G., et al.
Publicado: (2011)

Beta-blocking agents in cardiovascular disease; are they here to stay?
por: van der Wall, E. E.
Publicado: (2014)

Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease
por: Weng, Yunqi, et al.
Publicado: (2017)

Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
por: Kohsaka, Shun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fep0m9e34qeuqf5ojl53ho5sm